Grifols names new senior executives

Barcelona, Spain, Feb. 1, 2024 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has served patients and society for 115 years, today announced it has reinforced its senior management team with two appointments. Roland Wandeler, Ph.D., is the new President of its Biopharma Business Unit, while Camille Alpi begins as Chief Human Resources and Talent Officer.

Dr. Wandeler brings more than two decades of global biopharmaceutical experience to Grifols. He has a track record of driving commercial, operational and organizational excellence throughout his career in both Europe and the United States. This includes being Chief Commercial Officer at MorphoSys, where he helped build a fully integrated biopharmaceutical company. Prior to that, Mr. Wandeler worked for 14 years at Amgen, where he held executive positions of increasing responsibility, including Corporate Vice President and General Manager Bone Health and Cardiology in the U.S., a multibillion growth business. He replaces Joel Abelson, who is retiring.

Dr. Wandeler is a graduate of the Swiss Federal Institute of Technology (ETH), in Zurich. He holds a doctorate in technical sciences as well as Master of Science in chemical engineering. He is located in Grifols’ corporate offices in North Carolina’s Research Triangle Park, not far from the company’s flagship plasma-medicines manufacturing site in Clayton, N.C.

Mr. Alpi is an international HR executive with 20 years of experience across Europe, the U.S., South America and Asia. Prior to coming to Grifols, he was Vice President Human Resources for Danone Specialized Nutrition, the company’s healthcare division. Here he drove HR initiatives at the local, regional and global levels, focusing on talent and organizational development, employee experience and engagement, as well as transformation and change management.

Mr. Alpi has a master’s degree in business and economics from Uppsala University, Sweden. He is based in the company’s global headquarters, in Sant Cugat (Barcelona), and takes over from Montse Gaja, who has decided to retire.

Following handovers from their predecessors, Dr. Wandeler and Mr. Alpi report to Víctor Grifols Deu, Chief Operating Officer. “We are delighted to welcome both Camille and Roland to Grifols, where we continue to build a world-class, talented executive team,” said Mr. Grifols Deu. “Their broad international experience in their respective areas of expertise will contribute greatly to our leadership in providing more medicines to more patients in more parts of the world.”

“I am honored to be joining the team at Grifols, a pioneer and leader in essential plasma-derived therapies, and a prestigious name in healthcare that stands for high quality trusted medicines,” said Mr. Wandeler. “Throughout my career, in markets around the world, I have been passionate about building and leading diverse, high-performing teams and driving innovation for patients. With its portfolio of life-changing medicines across a wide range of therapeutic areas, Grifols is uniquely positioned to make a difference for patients, true to their mission to enable people to lead better-quality lives.”

“This is as an exciting time as ever to become part of Grifols, a preeminent organization thoroughly committed to strengthening and building its motivated performance-driven culture to provide lifesaving medicines and solutions to patients,” stated Mr. Alpi. “I look forward to leading this company’s progressive forward-thinking HR function and doing what I can to make Grifols an even more attractive workplace for inspired people who want a lasting career making a positive impact in the health and quality of life of individuals.”

The new appointments round out an enhanced senior leadership team whose recent additions include Jörg Schüttrumpf as Chief Scientific Innovation Officer and Miguel Louzan, Chief Digital Information Officer.